LYRA vs. PYPD, NEPH, TTOO, PAVM, MHUA, IINN, ICU, MDAI, NMTC, and GCTK
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include PolyPid (PYPD), Nephros (NEPH), T2 Biosystems (TTOO), PAVmed (PAVM), Meihua International Medical Technologies (MHUA), Inspira Technologies Oxy B.H.N. (IINN), SeaStar Medical (ICU), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), and GlucoTrack (GCTK). These companies are all part of the "surgical & medical instruments" industry.
PolyPid (NASDAQ:PYPD) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.
PolyPid has higher earnings, but lower revenue than Lyra Therapeutics. PolyPid is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, PolyPid and PolyPid both had 8 articles in the media. Lyra Therapeutics' average media sentiment score of 0.71 beat PolyPid's score of -0.14 indicating that PolyPid is being referred to more favorably in the media.
PolyPid has a net margin of 0.00% compared to PolyPid's net margin of -4,099.82%. PolyPid's return on equity of -77.34% beat Lyra Therapeutics' return on equity.
PolyPid received 1 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 74.19% of users gave PolyPid an outperform vote while only 61.11% of users gave Lyra Therapeutics an outperform vote.
PolyPid has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
PolyPid currently has a consensus price target of $14.00, suggesting a potential upside of 195.36%. Lyra Therapeutics has a consensus price target of $7.13, suggesting a potential upside of 1,902.53%. Given PolyPid's higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than PolyPid.
26.5% of PolyPid shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 17.4% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
PolyPid beats Lyra Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
